XML 19 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
FINANCIAL INSTRUMENTS
6 Months Ended
Jun. 30, 2012
FINANCIAL INSTRUMENTS [Abstract]  
FINANCIAL INSTRUMENTS
NOTE 4-FINANCIAL INSTRUMENTS
Investments in Debt and Equity Securities
The fair values of the Company's available-for-sale securities are based on quoted market prices and are included in cash and cash equivalents, available-for-sale securities-short-term and available-for-sale securities-long-term on the accompanying Condensed Consolidated Balance Sheets based on each respective security's maturity.
As described in further detail in Note 2. "Acquisition", during the three months ended June 30, 2012, the Company liquidated the majority of its available-for-sale securities as part of the Acquisition. The available-for-sale securities were sold for total cash consideration of $52.0 million and the resulting net gain on sale of $0.5 million was recognized in Interest income and other, net in the accompanying Condensed Consolidated Statements of Operations.
The following is a summary of available-for-sale securities as of June 30, 2012 (in thousands):
 
 
 
Gross
 
 
Gross
 
 
 
 
Amortized
 
 
Unrealized
 
 
Unrealized
 
 
 
 
Cost
 
 
Gains
 
 
Losses
 
 
Fair Value
 
U.S. government obligations and agency securities
 
7,286
 
 
66
 
 
-
 
 
7,352
 
U.S. corporate debt
 
 
653
 
 
 
14
 
 
 
-
 
 
 
667
 
Foreign corporate debt and equity securities
 
 
2,099
 
 
 
33
 
 
 
-
 
 
 
2,132
 
Total available-for-sale securities
 
10,038
 
 
113
 
 
-
 
 
10,151
 

The following is a summary of available-for-sale securities as of December 31, 2011 (in thousands):
 
 
 
Gross
 
 
Gross
 
 
 
 
Amortized
 
 
Unrealized
 
 
Unrealized
 
 
 
 
Cost
 
 
Gains
 
 
Losses
 
 
Fair Value
 
U.S. government obligations and agency securities
 
19,421
 
 
177
 
 
-
 
 
19,598
 
U.S. corporate debt
 
 
24,942
 
 
 
259
 
 
 
(101
)
 
 
25,100
 
Foreign government obligations and agency securities
 
 
2,805
 
 
 
6
 
 
 
(1
)
 
 
2,810
 
Foreign corporate debt and equity securities
 
 
15,157
 
 
 
41
 
 
 
(268
)
 
 
14,930
 
Total available-for-sale securities
 
62,325
 
 
483
 
 
(370
)
 
62,438
 

Contractual maturities of available-for-sale securities as of June 30, 2012 and December 31, 2011 are as follows (in thousands):
 
 
June 30,
  
December 31,
 
 
 2012  
2011
 
Less than one year
 
2,239
  
7,937
 
One to two years
  
6,117
   
25,785
 
More than two years
  
1,795
   
28,716
 
Total available-for-sale securities
 
10,151
  
62,438
 

The Company recognized no significant net realized gains and losses during the three months and six months ended June 30, 2011. Realized gains and losses are included in Interest income and other, net in the accompanying Condensed Consolidated Statements of Operations.
Non-Marketable Securities
As of June 30, 2012 and December 31, 2011, the carrying amounts of the Company's non-marketable securities, totaling $5.0 million, equaled their estimated fair values. The estimated fair value was primarily determined to be the initial cost basis plus the Company's allocated share of results and any other-than-temporary impairment ("OTTI") recognized. There was no OTTI recognized during the six months ended June 30, 2012. During the six months ended June 30, 2011, the Company recognized an expense totaling $1.2 million in interest income and other, net related to its limited partnership investment fund. Net investment results are included in interest income and other, net in the accompanying Condensed Consolidated Statements of Operations. Depending on market conditions, the Company may incur additional charges on this investment portfolio in the future.
Debt Obligations
Debt obligations are not recorded at fair value on a recurring basis and are carried at amortized cost. The fair value of debt obligations was based on recent transactions and categorized within level 3 of the fair value hierarchy.
The carrying value and fair value of the Company's 3.50% Senior Convertible Notes due 2039 (the "3.50% Notes") of $3.9 million is classified in current liabilities on the accompanying Condensed Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011. During the first quarter of 2012, the Company repurchased approximately $91.6 million of aggregate principal amount of its Notes due in 2038 in private transactions for total cash consideration of $92.1 million, including accrued interest of $0.5 million. The Notes were purchased at par and based on this recent transaction, the Company concluded that the carrying value approximated fair value as of June 30, 2012.
On June 25, 2012, the Company issued 4.00% Notes in a registered offering for an aggregate principal amount of $105.0 million. As of June 30, 2012, the carrying value and fair value of the 4.00% Notes was $105.0 million.
On June 25, 2012, the Company entered into a Credit Agreement and borrowed $85.0 million under the Term Loan. As of June 30, 2012, the carrying value and fair value of the Term Loan was $85.0 million.
As of June 30, 2012, the carrying value of the 4.00% Notes and Term Loan approximates its fair value. Refer to Note 9. "Long-Term Debt Obligations" for further information.
Derivative Financial Instruments
The Company derives a portion of its revenues in foreign currencies, predominantly in Europe and Japan, as part of its ongoing business operations. In addition, a portion of its assets are held in the nonfunctional currencies of its subsidiaries. The Company enters into foreign currency forward contracts to manage a portion of the volatility related to transactions that are denominated in foreign currencies. The Company's foreign currency forward contracts are entered into for periods consistent with the related underlying exposures and do not constitute positions that are independent of those exposures. The Company's accounting policies for these instruments are based on whether the instruments are classified as designated or non-designated hedging instruments. The Company recognizes derivatives on its Condensed Consolidated Balance Sheets at fair value. The effective portions of designated cash flow hedges are recorded in other comprehensive income ("OCI") until the hedged item is recognized in earnings. As of June 30, 2012, the Company's existing foreign currency forward exchange contracts mature within 12 months. The deferred amount related to the Company's derivatives currently recorded in OCI and expected to be recognized into earnings over the next 12 months is a net gain of $0.6 million. Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings.
Derivative instruments designated as cash flow hedges must be de-designated as hedges when it is probable the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Deferred gains and losses in OCI associated with such derivative instruments are reclassified immediately into operations through other income and expense. Any subsequent changes in fair value of such derivative instruments are reflected in other income and expense unless they are re-designated as hedges of other transactions. The Company did not recognize any net gains or losses related to the loss of hedge designation on discontinued cash flow hedges during the three and six months ended June 30, 2012 and 2011.
As of June 30, 2012 and December 31, 2011, the total notional values of the Company's foreign currency forward contracts that mature within 12 months were as follows (in thousands):
 
 
June 30,
 
 
December 31,
 
 
 2012  2011 
Euro
 
15,385
  
11,851
 
Japanese yen
  
7,265
   
7,008
 
British pound
  
5,052
   
4,459
 
Total
 
27,702
  
23,318
 

The Company did not have any contracts that were not designated or qualifying as hedges as of June 30, 2012 and December 31, 2011.
As a result of the use of derivative instruments, the Company is exposed to the risk that the counterparties may be unable to meet the terms of the agreements. To mitigate the risk, only contracts with carefully selected highly-rated major financial institutions are entered into. In the event of non-performance by these counterparties, the asset position carrying values of the financial instruments represent the maximum amount of loss that can be incurred; however, no losses as a result of counterparty defaults are expected. The Company does not require and is not required to pledge collateral for these financial instruments. The Company does not enter into foreign currency forward contracts for trading or speculative purposes and is not party to any leveraged derivative instruments.
The following table shows the Company's foreign currency derivatives measured at fair value as reflected on the accompanying Condensed Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011 (in thousands):
 
June 30,
December 31,
Balance Sheet
 
 2012
 2011
Location
Derivative assets:
   
Foreign exchange contracts
681
940
 Other current assets
Derivative liabilities:
   
Foreign exchange contracts
128
217
 Accrued expenses

The following table shows the effect, net of tax, of the Company's derivative instruments on the accompanying Condensed Consolidated Statements of Operations and OCI for the three and six months ended June 30, 2012 and 2011 (in thousands):
  
 
Three Months Ended June 30,
 
 
Six Months Ended June 30,
 
 
 
2012
 
 
2011
 
 
2012
 
 
2011
 
Derivatives in cash flow hedging relationships:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net gain (loss) recognized in OCI, net of tax (1)
 
$
248
 
 
$
(50
)
 
 
(268
)
 
 
(50
)
Net gain reclassified from accumulated OCI into income, net of tax (2)
 
 
697
 
 
 
-
 
 
 
1,215
 
 
 
-
 
Net gain (loss) recognized in other income and expense (3)
 
 
3
 
 
 
(13
)
 
 
28
 
 
 
(13
)
Derivatives not designated as hedging relationships:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) recognized in other income and expense (4)
 
 
22
 
 
 
(613
)
 
 
(126
)
 
 
(2,517
)
______________________
(1)
Net change in the fair value of the effective portion classified in OCI
(2)
Effective portion classified as revenue
(3)
Ineffective portion and amount excluded from effectiveness testing classified as Interest and other, net
(4)
Classified in Interest and other, net